Israel HER-2 Negative Breast Cancer Market (2025-2031) | Outlook, Analysis, Companies, Segmentation, Share, Industry, Trends, Value, Competitive Landscape, Growth, Size & Revenue, Forecast

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Israel Country Macro Economic Indicators

3.2 Israel HER-2 Negative Breast Cancer Market Revenues & Volume, 2021 & 2031F

3.3 Israel HER-2 Negative Breast Cancer Market - Industry Life Cycle

3.4 Israel HER-2 Negative Breast Cancer Market - Porter's Five Forces

3.5 Israel HER-2 Negative Breast Cancer Market Revenues & Volume Share, By Treatment, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing awareness about breast cancer screening and early detection efforts in Israel

4.2.2 Advancements in targeted therapies and personalized medicine for HER-2 negative breast cancer

4.2.3 Growing investments in healthcare infrastructure and research and development in Israel

4.3 Market Restraints

4.3.1 High treatment costs associated with targeted therapies for HER-2 negative breast cancer

4.3.2 Limited access to specialized healthcare services in certain regions of Israel

4.3.3 Regulatory challenges and approval processes for new treatments in the Israeli market

6.1 Israel HER-2 Negative Breast Cancer Market, By Treatment

6.1.1 Overview and Analysis

6.1.2 Israel HER-2 Negative Breast Cancer Market Revenues & Volume, By Treatment, 2021- 2031F

6.1.3 Israel HER-2 Negative Breast Cancer Market Revenues & Volume, By Chemotherapy, 2021- 2031F

6.1.4 Israel HER-2 Negative Breast Cancer Market Revenues & Volume, By Radiation Therapy, 2021- 2031F

6.1.5 Israel HER-2 Negative Breast Cancer Market Revenues & Volume, By Hormonal Therapy, 2021- 2031F

6.1.6 Israel HER-2 Negative Breast Cancer Market Revenues & Volume, By Others, 2021- 2031F

7.1 Israel HER-2 Negative Breast Cancer Market Export to Major Countries

7.2 Israel HER-2 Negative Breast Cancer Market Imports from Major Countries

8.1 Percentage of population undergoing regular breast cancer screenings

8.2 Number of clinical trials for HER-2 negative breast cancer therapies conducted in Israel

8.3 Adoption rate of personalized medicine approaches in the treatment of HER-2 negative breast cancer

9.1 Israel HER-2 Negative Breast Cancer Market Opportunity Assessment, By Treatment, 2021 & 2031F

10.1 Israel HER-2 Negative Breast Cancer Market Revenue Share, By Companies, 2024

10.2 Israel HER-2 Negative Breast Cancer Market Competitive Benchmarking, By Operating and Technical Parameters